APC anti-mouse CD49b (pan-NK cells) Antibody

Pricing & Availability
Clone
DX5 (See other available formats)
Regulatory Status
RUO
Other Names
α2 integrin, VLA-2 α chain, DX5, Integrin α2 chain, ITGA2
Isotype
Rat IgM, κ
Ave. Rating
Submit a Review
Product Citations
publications
DX5_APC_100507
C57BL/6 mouse splenocytes stained with NK1.1 PE and DX5 APC
  • DX5_APC_100507
    C57BL/6 mouse splenocytes stained with NK1.1 PE and DX5 APC
See APC spectral data
Cat # Size Price Quantity Check Availability Save
108909 25 µg 67€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
108910 100 µg 214€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

DX5 antigen has been recently characterized as CD49b. It is a 150 kD integrin α chain also known as α2 integrin, VLA-2 α chain, and integrin α2 chain. CD49b non-covalently associates with CD29 (β1 integrin) to form the CD49b/CD29 complex known as VLA-2, a receptor for collagen and laminin. CD49b is expressed on platelets, the majority of NK cells, NKT cells, and a small subset of CD8+ T cells (this population can be significantly increased following viral infection). DX5 is used for the identification and isolation of NK cells, and is especially useful for identifying NK cells in mice lacking the NK1.1 antigen.

Product Details
Technical Data Sheet (pdf)

Product Details

Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
IL-2-propagated NK1.1+ cells from C57BL/6 mice
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified with APC under optimal conditions, and is at >85% purity.
Concentration
0.2 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested

Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤0.25 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Red Laser (633 nm)
Application Notes

The DX5 clone detects cells expressing relatively high levels of CD49b and may not be useful for the detection of cells expressing low levels of CD49b. DX5 does not block NK cell killing or binding to collagen in vitro. Additional reported applications (for the relevant formats) include: complement-mediated cytotoxicity2 and immunohistochemical staining5 of formalin-fixed and paraffin-embedded tissue sections as well as immunohistochemical staining of acetone-fixed frozen sections10. The binding of DX5 antibody to splenic NK cells can be blocked by HMa2 antibody.

Application References

(PubMed link indicates BioLegend citation)
  1. Arase H, et al. 2001. J. Immunol. 167:1141. (FC)
  2. Sepulveda H, et al. 1999. J. Immunol. 163:1133.
  3. Norian LA and Allen PM. 2004. J. Immunol. 173:835. (FC)
  4. Andoniou CE, et al. 2005. Nature Immunology 6:1011.
  5. Oertelt S, et al. 2006. J. Immunol. 177:1655. (IHC) PubMed
  6. Bourdeau A, et al. 2007. Blood doi:10.1182/blood-2006-08-044370.
  7. Charles N, et al. 2010. Nat. Med. 16:701. (FC) PubMed
  8. Qui Q, et al. 2010. J. Immunol. 184:1681. (FC) PubMed
  9. Busche A, et al. 2011. J. Immunol. 186:2918. PubMed
  10. Kim HR, et al. 2011. Nephrology 16:545. (IHC) PubMed
  11. Seyoum B, et al. 2011. Vaccine. 29:8002. PubMed
  12. Younos IH, et al. 2012. Int Immunopharmacol. 13:245. PubMed
  13. Honjo K, et al. 2012. PNAS. PubMed.
  14. Huang HN, et al. 2013. Biomaterials. 34:10151. PubMed
Product Citations
  1. Ye Y, et al. 2017. Sci Immunol. 2:17. PubMed
  2. Best SA, et al. 2018. Cell Metab. 27:935. PubMed
  3. Gentek R, et al. 2018. Immunity. 48:1160. PubMed
  4. Shan M et al. 2018. Immunity. 49(4):709-724 . PubMed
  5. Braza MS et al. 2018. Immunity. 49(5):819-828 . PubMed
  6. LaFleur MW, et al. 2019. Nat Commun. 10:1668. PubMed
  7. Hu J, et al. 2019. Mol Ther Nucleic Acids. 16:650. PubMed
  8. Page N, et al. 2018. Immunity. 48:937. PubMed
  9. Niemann J, et al. 2019. Nat Commun. 10:3236. PubMed
  10. Denny JE, et al. 2019. Sci Rep. 2.786111111. PubMed
  11. Fujita K, et al. 2019. Proc Natl Acad Sci U S A. 116:14714. PubMed
  12. Thi VAD, et al. 2019. Mol Cells. 42:869. PubMed
  13. Rohner L, et al. 2020. Sci Rep. 0.570833333. PubMed
  14. Mandour MF, et al. 2020. Infect Agent Cancer. 15:30. PubMed
  15. Liu Z, et al. 2020. Cell. 178(6):1509-1525.e19.. PubMed
  16. Ludwik KA, et al. 2020. Cell Reports. 32(3):107931. PubMed
  17. Liu Z, et al. 2020. STAR Protoc. 1:100029. PubMed
  18. Cohen M, et al. 2010. J Immunol. 185:5869. PubMed
  19. Pinto AR, et al. 2012. PLoS One. 7:e36814. PubMed
  20. Younos I, et al. 2012. Int Immunopharmacol. 13:245. PubMed
  21. Honjo K, et al. 2012. Proc Natl Acad Sci U S A. 109:15882. PubMed
  22. Seyoum B, et al. 2011. Vaccine. 29:8002. PubMed
  23. Tassi I, et al. 2014. J Immunol. 193:4303. PubMed
  24. Jovicic N, et al. 2015. PLoS One. 10: 0134089. PubMed
  25. JI B, et al. 2016. Cell Death Differ. 23:759-75. PubMed
  26. Pelly V, et al. 2016. Mucosal Immunol. 10.1038/mi.2016.4. PubMed
  27. Ho V, et al. 2016. PLoS One. 11:e0168072. PubMed
  28. Ludwik KA, et al. 2021. STAR Protocols. 2(1):100270. PubMed
  29. Wang J, et al. 2020. Cell. 183(7):1867-1883.e26. PubMed
  30. Shannon JP, et al. 2021. Immunity. 54(2):276-290.e5. PubMed
  31. Bonavita E, et al. 2020. Immunity. 1215:53. PubMed
  32. Yoon Y, et al. 2021. Cancers (Basel). 13: . PubMed
  33. Liu X, et al. 2021. Adv Sci (Weinh). 8:e2100233. PubMed
  34. Yang C, et al. 2021. J Immunother Cancer. 9:. PubMed
  35. Shannon JP, et al. 2021. STAR Protoc. 2:100790. PubMed
  36. Jee JJ, et al. 2022. Nat Commun. 13:18. PubMed
  37. Zhou J, et al. 2022. Int J Oncol. 61: . PubMed
  38. , et al. 2021. Eur J Immunol. 51:2708. PubMed
  39. Chen J, et al. 2022. J Nanobiotechnology. 20:283. PubMed
  40. Do-Thi VA, et al. 2021. Cancers (Basel). 13:. PubMed
  41. del Rio ML, et al. 2021. Transl Res. Online ahead of print.. PubMed
  42. Barsoumian HB, et al. 2022. Cancers (Basel). 14:. PubMed
  43. Bell CR, et al. 2022. Nat Commun. 13:2063. PubMed
  44. Kim S, et al. 2022. Cancers (Basel). 14:. PubMed
  45. Aghayev T, et al. 2022. Cancer Discov. 12:1960. PubMed
  46. del Rio ML, et al. 2022. Front Immunol. 13:887348. PubMed
  47. Mandour MF, et al. 2023. Front Med (Lausanne). 9:1057252. PubMed
  48. del Rio ML, et al. 2023. Front Immunol. 14:1113858. PubMed
  49. Rabia E, et al. 2023. Front Immunol. 14:1168444. PubMed
RRID
AB_313416 (BioLegend Cat. No. 108909)
AB_313417 (BioLegend Cat. No. 108910)

Antigen Details

Structure
Integrin α chain, 150 kD
Distribution

NK cells, subset of T cells

Function
Adhesion
Ligand/Receptor
Collagen, laminin
Cell Type
NK cells, T cells
Biology Area
Cell Adhesion, Cell Biology, Immunology, Innate Immunity
Molecular Family
Adhesion Molecules, CD Molecules
Antigen References

1. Arase H, et al. 2001. J. Immunol. 167:1141.
2. Barclay AN, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
3. Sasaki K, et al. 2003. Int. Immunol. 15:701.
4. Inoue O, et al. 2003. J. Cell Biol. 160:769.

Gene ID
16398 View all products for this Gene ID
UniProt
View information about CD49b on UniProt.org
Go To Top Version: 1    Revision Date: 11.30.2012

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere

Login / Register
Remember me
Forgot your password? Reset password?
Create an Account